Advertisement
Advertisement
U.S. markets close in 4 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Acurx Pharmaceuticals, Inc. (ACXP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.3100-0.1250 (-2.82%)
As of 03:49PM EST. Market open.
Advertisement

Acurx Pharmaceuticals, Inc.

259 Liberty Avenue
Staten Island, NY 10305
United States
917-533-1469
https://www.acurxpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees2

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert J. DeLucciaCo-Founder & Exec. Chairman342.75kN/A1946
Mr. David P. Luci C.P.A., CPA, Esq., J.D.Co-Founder, Pres, CEO & Director321.21kN/A1967
Mr. Robert G. Shawah CPACo-Founder & CFO90kN/A1967
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.

Corporate Governance

Acurx Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement